1. Home
  2. CUE vs PZG Comparison

CUE vs PZG Comparison

Compare CUE & PZG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • PZG
  • Stock Information
  • Founded
  • CUE 2014
  • PZG 1992
  • Country
  • CUE United States
  • PZG United States
  • Employees
  • CUE N/A
  • PZG N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • PZG Metal Mining
  • Sector
  • CUE Health Care
  • PZG Basic Materials
  • Exchange
  • CUE Nasdaq
  • PZG Nasdaq
  • Market Cap
  • CUE 59.5M
  • PZG 48.4M
  • IPO Year
  • CUE 2018
  • PZG 1999
  • Fundamental
  • Price
  • CUE $0.72
  • PZG $1.07
  • Analyst Decision
  • CUE Strong Buy
  • PZG
  • Analyst Count
  • CUE 2
  • PZG 0
  • Target Price
  • CUE $3.00
  • PZG N/A
  • AVG Volume (30 Days)
  • CUE 132.0K
  • PZG 845.3K
  • Earning Date
  • CUE 11-13-2025
  • PZG 11-11-2025
  • Dividend Yield
  • CUE N/A
  • PZG N/A
  • EPS Growth
  • CUE N/A
  • PZG N/A
  • EPS
  • CUE N/A
  • PZG N/A
  • Revenue
  • CUE $8,286,000.00
  • PZG N/A
  • Revenue This Year
  • CUE N/A
  • PZG N/A
  • Revenue Next Year
  • CUE $13.27
  • PZG N/A
  • P/E Ratio
  • CUE N/A
  • PZG N/A
  • Revenue Growth
  • CUE N/A
  • PZG N/A
  • 52 Week Low
  • CUE $0.45
  • PZG $0.31
  • 52 Week High
  • CUE $1.99
  • PZG $1.20
  • Technical
  • Relative Strength Index (RSI)
  • CUE 34.73
  • PZG 73.05
  • Support Level
  • CUE $0.77
  • PZG $0.98
  • Resistance Level
  • CUE $0.78
  • PZG $1.07
  • Average True Range (ATR)
  • CUE 0.03
  • PZG 0.07
  • MACD
  • CUE -0.01
  • PZG -0.01
  • Stochastic Oscillator
  • CUE 9.53
  • PZG 51.85

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

Share on Social Networks: